Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID‐19

Pharmacology Research and Perspectives - Tập 8 Số 5 - 2020
Paula Maria Heister1, Robin N. Poston2
1University of Cambridge, Cambridge, United Kingdom
2Queen Mary University of London, London, United Kingdom

Tóm tắt

AbstractMore than ten million patients worldwide have been diagnosed with coronavirus disease 19 (COVID‐19) to date (WHO situation report, 1st July 2020). There is no vaccine to prevent infection with the causative organism, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), nor a cure. In the struggle to devise potentially useful therapeutics in record time, the repurposing of existing compounds is a key route of action. In this hypothesis paper, we argue that the bisbenzylisoquinoline and calcium channel blocker tetrandrine, originally extracted from the plant Stephania tetrandra and utilized in traditional Chinese medicine, may have potential in the treatment of COVID‐19 and should be further investigated. We collate and review evidence for tetrandrine's putative mechanism of action in viral infection, specifically its recently discovered antagonism of the two‐pore channel 2 (TPC2). While tetrandrine's particular history of use provides a very limited pharmacological dataset, there is a suggestion from the available evidence that it could be effective at doses used in clinical practice. We suggest that further research to investigate this possibility should be conducted.

Từ khóa


Tài liệu tham khảo

Chen KK, 1935, The alkaloids of han‐fang‐chi, J Biol Chem, 109, 681, 10.1016/S0021-9258(18)75199-5

10.1111/j.1527-3466.1998.tb00341.x

10.1007/s11101-020-09673-w

10.1039/D0OB00078G

10.3390/molecules16098020

10.1016/j.biopha.2017.10.116

Shangbin Q, 1986, harmacology and Applications of Chinese Materia Medica (Volume I), 400

10.1038/s41467-020-15562-9

10.1126/science.1258758

King VF, 1988, Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin, J Biol Chem, 263, 2238, 10.1016/S0021-9258(18)69196-3

10.1101/cshperspect.a035071

10.1128/MCB.00113-14

10.1016/j.ceca.2020.102212

10.1038/nature08030

10.1042/BJ20060759

10.1016/j.cell.2012.08.036

10.7554/eLife.54712

The Human Protein Atlas.2020https://www.proteinatlas.org/ENSG00000162341‐TPCN2/tissue

10.1016/j.bbamcr.2018.05.004

10.1016/j.ceca.2018.08.003

DobsonSJ MankouriJ WhitehouseA. A requirement for potassium and calcium channels during the endolysosomal trafficing of polyomavirus virions. bioR.xiv preprint 2019.

10.1038/nchembio.150

10.3390/cells8101144

10.1038/sj.bjp.0701295

10.1126/scisignal.2005450

10.3390/cells9010094

10.1038/s41422-019-0214-z

10.1038/s41586-020-2286-9

10.3390/biom9110696

10.1097/00005344-199210000-00001

10.1016/0024-3205(94)00952-X

Dai GZ, 1990, Intravenous tetrandrine in terminating acute episodes of paroxysmal supraventricular tachycardia, Chin Med, 103, 460

10.1093/cvr/cvaa106

BNF 79 March‐September 2020 RCPCH Publications Ltd 2020.

10.1097/00005344-198511000-00004

10.1177/030089161009600314

10.1111/j.2042-7158.1998.tb03344.x

10.1016/S0024-3205(96)00552-8

10.1159/000137801

Guan S, 2001, Effect of tetrandrine on cellular electrophysiology and calcium uptake of myocardium in guinea pigs and dogs, Chin Med J, 114, 1046

10.15252/embj.2019104058

Sun J, 2019, Clinical efficacy of acetylcysteine combined with tetrandrine tablets in the treatment of silicosis and the effect on serum IL‐6 and TNF‐alpha, Exp Ther Med, 18, 3383

Zhang J, 2020, Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF‐beta1 and MMP‐7 in silicosis patients, Exp Ther Med, 19, 2195

10.1111/j.1365-2249.1990.tb05239.x

10.1002/jor.23155

Seow WK, 1989, Suppression of human monocyte interleukin 1 production by the plant alkaloid tetrandrine, Clin Exp Immunol, 75, 47

10.1016/S0140-6736(20)30183-5

10.1016/j.jinf.2020.04.012

10.1038/s41577-020-0311-8

Remy K, 2020, Immunotherapies for COVID‐19: lessons learned from sepsis, Lancet Respir Med, 1

10.1159/000237137

10.1159/000235019

10.1111/bcp.12419

10.1097/CCM.0000000000002550

10.3390/ijms19092465

10.1038/ncomms5699

10.1016/0147-6513(82)90034-3

10.1007/s11655-015-2303-2

10.1021/tx200290s

10.1007/s00280-007-0420-0

Kannan S, 2014, Cochrane Database of Systematic Reviews

10.1016/j.clpt.2005.04.005

10.1126/science.aaa8121

10.1155/2018/6763057

Xie QM, 2002, Pharmacological actions of tetrandrine in inflammatory pulmonary diseases, Acta Pharmacol Sin, 23, 1107

10.1016/j.jchromb.2017.10.048

Dong Q‐K, 2011, Study on the pharmacokinetics of tetrandrine tablets in healthy volunteers, J Clin Med Pract, 15, 83

10.1016/B978-0-12-590450-6.50010-0

10.1021/acs.molpharmaceut.0c00026

10.7150/thno.30408

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.2005.

Government UK, Medicines (Aristolochia and Mu Tong etc.) (Prohibition) Order 2001, SI 2001/1841

10.1186/s12985-016-0479-5

10.1007/s00335-018-9760-9

10.1002/ame2.12108

Cohen J, 2020, Mice, hamsters, ferrets, monkeys. Which lab animals can help defeat the new coronavirus?, Science

10.1093/jac/dkm476

Thông tin
Thông tin xuất bản

Pharmacology Research and Perspectives

Tập 8 Số 5

Thông tin tác giả